Please click on the following links to see the available presentations (authorised by the Authors):
DMPK-Centered Approach to Predict Drug Efficacy and Safety
Program here : Flyer GMP 2019
16th to 18th October 2019
Château de Montchat – Lyon, France
In France, the conduct of clinical trials requires a prior express favourable opinion of a Committee for the protection of the persons, in French Comité de protection des personnes (CPP).
The competent CPPs have been designated randomly, by means of a draw since a law of 2012, implemented in November 2016. However, the random designation did not take into account the workload of the CPPs or the skills of their members, which contributed to difficulties and delays.
The AFPT – Club Phase 1 had participated with France Biotech, AFCROs and DITEP in the writting of the open letter of 17 December 2017 to alert the Minister of Health to the necessity of reforming the process for the selection of CPPs.
Therefore, the AFPT – Club Phase 1 welcomes the adoption of the new Law No. 2018-892 of 17 October 2018 which stipulates that the CPP will now be randomly drawn among the committees available and with the required skills for the project review. This marks a major step towards improving the competitiveness of France in Clinical Trials.
Registration for the 2019 conference of the European Federation for Exploratory Medicines Development (EUFEMED) is now open!
The event will be held from May 15 – 17, 2019 in Lyon, France.
The conference once again has an exciting scientific programme: The Changing Landscape of Early Medicines Development: Be Prepared!
The two-day meeting will include a mixture of focused scientific sessions, interactive workshops and open forum panel discussions. Two parallel, pre-conference workshops will take place on 15 May 2018 and are dedicated to “Trial Simulation and Basic Tools” and “Early Clinical Development of Biologics – What is Special?”
Please join us in Lyon, France on May 15-17, 2019!
On 19 September, EUFEMED organized a successful Forum discussion at the University of Leuven in Belgium. The audience was invited to directly interact with the panel of regulators, leading to fruitful discussions to identify and mitigate risks for first-in-human and early clinical trials. Thanks to the speakers for contributing to the great success of this forum!
The presentations are available on the following link: http://www.eufemed.eu/19-sep-2018-eufemed-first-forum-ku-leuven-belgium/
For the 30th annual meeting of GMP, the AFPT president, Henri Caplain, MD, MSc gave an interesting and informative presentation focussed on the question “Transporter-medicated DDIs, are they clinically relevant?”
Download the presentation below:
Download the presentations here :
Wednesday April 25th to Friday April 27th
27th AGAH Annual Meeting 2018
We are most happy to invite you to the AGAH Annual Meeting in April 2018 in Munich.
The conference will focus on how to predict as well as on how to prevent adverse drug reactions in early phase drug development. The major target organ systems will be addressed: liver, kidney, CNS, cardiac function. Further sessions will be dedicated to local tolerance and immunotoxicity.
Click on the following link: Registration_form_04_05April2018_v19Mar2018
AFPT-Club Phase 1
French association of the professionals of human and translational pharmacology
34, avenue des Champs-Elysées 75008 Paris 8ème, France
A founding member of